Drug intelligence / Profile preview

CL-S03

Development stage: Preclinical
Lead developer: Celex Oncology

Overview

CL-S03 is a drug candidate initially developed by Celex Oncology Innovations Ltd. Its current global highest R&D status is Preclinical, and its primary therapeutic area is neoplasms (cancer). The specific mechanism of action, target, and drug type are currently unknown[8].

Beyond the preview

Go deeper on CL-S03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CL-S03.

Explore the full profile